RANKINGS

POPULAR STOCKS

Alar Pharmaceuticals Inc.

Taipei Exchange:6785.TWO

Location

Taiwan

Market Cap

USD 319.33 M

Share Price

USD 4.78

Avg Daily Volume

154,950

Change (1 day)

-0.53%

Change (1 year)

Change (YTD)

10.93%

Alar Pharmaceuticals Inc. Price to Earnings Ratio (P/E) on June 13, 2025: 577.08

Alar Pharmaceuticals Inc. Price to Earnings Ratio (P/E) is 577.08 on June 13, 2025. Price to earnings ratio compares the stock price to earnings per share; higher P/E suggests expectations for future earnings growth.
  • Alar Pharmaceuticals Inc. 52-week low Price to Earnings Ratio (P/E) is 636.45 on June 13, 2025, which is 10.29% above the current Price to Earnings Ratio (P/E).
  • Alar Pharmaceuticals Inc. 52-week low Price to Earnings Ratio (P/E) is 20.50 on June 13, 2025, which is -96.45% below the current Price to Earnings Ratio (P/E).
  • Alar Pharmaceuticals Inc. average Price to Earnings Ratio (P/E) for the last 52 weeks is 206.05.
Key data
Date Price to Earnings Ratio (P/E) Price to Book Ratio (P/B) Price to Sales Ratio (P/S) Enterprise Value to EBITDA (EV/EBITDA)
Market news
Taipei Exchange: 6785.TWO

Alar Pharmaceuticals Inc.

CEO Dr. Yung-Shun Wen Ph.D.
IPO Date Oct. 5, 2020
Location Taiwan
Headquarters No. 32, Keya Road
Employees 27
Sector 🏥 Health Care
Industries
Clinical Trials
💊 Pharmaceuticals
Description

Alar Pharmaceuticals Inc., a drug development company, focuses on developing long-acting release drug products for CNS disorders and chronic diseases in Taiwan. It is developing ALA-1000, which is in Phase II clinical trials for the treatment of opioid use disorder; ALA-1300 and ALA-2000, which is in pre-clinical stage for opioid use disorder; ALA-4000 which is in pre-clinical stage for treatment of Parkinson's disease; and ALA-3000, which is in pre-clinical stage for treating treatment-resistant depression. Alar Pharmaceuticals Inc. was founded in 2016 and is based in Taichung, Taiwan.

StockViz Staff

June 17, 2025

Any question? Send us an email